ADOCIA confirms PEA-PME eligibility

Lyon, France – (BUSINESS WIRE) – Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris: ADOC) is a clinical stage biopharmacy company specializing in the discovery and development of therapeutic solutions for the treatment of diabetes and other metabolic disorders, under the PEA tax system. We have confirmed that it will be targeted. – SME whose enforcement order was published in the official journal on March 4, 2014 (Law No. 2014-283) and came into effect on March 6, 2014.

To be eligible for PEA – PME, the market capitalization is less than € 1 billion, the number of employees is less than 5,000, the annual sales do not exceed € 1.5 billion, or the total balance sheet is less than € 2 billion.

Adocia meets all the criteria.

About Adoshia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions primarily in the areas of metabolic disorders such as diabetes and obesity. The company has a large portfolio of candidate drugs from three proprietary technology platforms.

1) Technology, BioChaperone®, Next-generation insulin and for the development of combinations that combine insulin with other hormone families. 2) AdOral®Oral peptide delivery technology; 3) TeenShell®An immunoprotective biomaterial for cell transplantation with the first application to pancreatic cells of so-called “unstable” diabetic patients.

Adocia has more than 25 patent families.

Based in Lyon, the company has approximately 115 employees. Adocia is a company listed on the Euronext marketTM Paris (Euronext: ADOC; ISIN: FR0011184241).


This press release contains forward-looking statements about Adocia and its business. Adocia believes that these forward-looking statements are based on reasonable assumptions. However, we cannot guarantee the achievement of the forecasts shown in these forward-looking statements. These forecasts are subject to risks, including those described in Adocia’s Universal Registration Document filed with the Autorité des marchés financial institution on April 21, 2022. Uncertainties inherent in Adocia’s website (, especially R & D, future clinical data, analysis, and economic conditions, financial markets, and market changes in which Adocia resides.

The forward-looking statements contained in this press release are also exposed to risks that Adocia does not know about or that Adocia does not consider materiality at this time. The realization of all or part of these risks may result in Adocia’s actual results, financial condition, performance or performance that differ materially from those expressed in these Declarations. .. This press release and the information contained therein do not constitute an offer to sell or subscribe, or solicit an order to purchase or subscribe to Adocia shares in any country.

contact address

Gerald Surah

[email protected]
+33 4 72 610 610

Ulysses Communication
Relationship between Adocia Press and Investors

Pierre Louis Germain
Arisak’s Margopeek Country
Bruno Arabian
[email protected]
+33 (0) 6 64 79 97 51